个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Yang, J.[1] * ; Li, A.[1] ; Feng, W. N.[2] ; Li, J.[3] ; Yan, H. H.[1] ; Xu, B. F.[1] ; Zhao, J.[4] ; Jia, Y.[5] ; Tang, K. J.[6] ; Li, Y. S.[7] ; Zhou, C. Z.[8] ; Fan, Y.[9] ; Xu, C. R.[1] ; Sun, Y. L.[1] ; Chen, H. J.[1] ;
机构： [1]Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China [2]First Peoples Hosp Foshan, Guangzhou, Peoples R China [3]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Affiliate Canc Hosp, Chengdu, Peoples R China [4]Beijing Canc Hosp, Beijing, Peoples R China [5]Dongguan Peoples Hosp, Dongguan, Peoples R China [6]Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China [7]Chongqing Univ Canc Hosp, Chongqing, Peoples R China [8]Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China [9]Zhejiang Canc Hosp, Hangzhou, Peoples R China
出处：
ISSN：

关键词： non small cell lung cancer EGFR mutation MET

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Yang J.,Li A.,Feng W. N.,et al.Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial[J].JOURNAL OF THORACIC ONCOLOGY.2024,19(10):S6-S6.
APA：
Yang, J.,Li, A.,Feng, W. N.,Li, J.,Yan, H. H....&Chen, H. J..(2024).Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial.JOURNAL OF THORACIC ONCOLOGY,19,(10)
MLA：
Yang, J.,et al."Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial".JOURNAL OF THORACIC ONCOLOGY 19..10(2024):S6-S6

相关文献

[1]Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer [2]Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer [3]A PROSPECTIVE, MOLECULAR EPIDEMIOLOGICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH ADENOCARCINOMA HISTOLOGY (PIONEER STUDY) - CHINA SUBSET ANALYSIS [4]Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer [5]Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [6]Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial [7]中国最大样本量探索EGFR非常见突变肺癌的预后和治疗模式 [8]The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis. [9]Cooperation of bisphosphonates with tyrosine kinase inhibitors in advanced non-small cell lung cancer with EGFR activation mutation: A retrospective study. [10]The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer

资源点击量：53080 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号